- The dental workforce trends that will dominate 2026
- Federal Medicaid cuts threaten dental care access: See the potential impact by state
- Children’s Mercy raises $150M for mental healthcare
- California awards $291M to expand behavioral health housing, services
- Think bigger – Turning AI from Trends to Long-Term Transformation
- UnityPoint Health hospital names market chief nursing officer
- OhioHealth builds well-being programs to reshape caregiver culture
- Washington hospital staff vote ‘no confidence’ in management company
- U of Mississippi Medical Center restores phone lines after cyberattack
- 13 health system IT leadership moves
- How health systems are repositioning informatics
- Mississippi hospital names COO
- Ex-Amazon Health leader joins Spotify founder’s health tech startup
- Know the True Value of Your Lab When an Offer Is on the Table
- U of California offers 32% wage hike in union talks
- UF Health taps new outpatient senior VP
- UAMS names new director of cardiovascular medicine division
- CMS’ add-on billing code boosts specialist pay: Study
- Lawmakers introduce bill to reverse Medicaid cuts, expand Medicare benefits
- Florida medical center to expand with ASC
- New Jersey woman charged with practicing unlicensed dentistry
- CMS extends hospital-at-home waivers for 5 years: What ASCs need to know
- 100+ organizations call on CMS to revise 2027 MA rates
- The retention breakthrough anesthesia needs
- Oklahoma advances interstate compact bill
- Brown University Health names new chief of cardiac surgery
- UNC Health Appalachian offers psychiatric physician training program
- Former PepperPointe Partnerships COO joins DPO
- The Smilist expands into Virginia
- Physician-led orthopedic ASC opens in Florida
- Colorado Medicaid ABA audit finds $77.8M in improper payments
- Georgia opens 30-bed forensic mental health unit to ease jail backlog
- Pennsylvania county cuts ribbon on $19.8M mental health diversion center
- Outpatient cardiology’s CMS whiplash
- 12 new ASCs in February
- UHS to roll out behavioral health revenue cycle AI tools in 2026
- UHS to roll out behavioral health revenue cycle AI tools in 2026
- 15 dentists making headlines
- CMS to suspend enrollment into Elevance’s Medicare Advantage plans
- Report: Most states investing in value-based care with Rural Health Transformation Program
- U.S. Tops 1,100 Measles Cases This Year as Outbreaks Grow
- FDA To Offer Cash Bonuses for Faster Drug Reviews
- 10 providers seeking RCM talent
- PDS Health added de novos across 3 states in February
- Novant posts 4.8% operating margin in 2025
- 'One2PrEP': Gilead's 1st Yeztugo DTC ad reimagines hit song to highlight biannual dosing
- Cleveland Clinic posts $913M operating income, 5% margin — 7 things to know
- Former Optum CEO Heather Cianfrocco to depart UnitedHealth Group
- New Drug, Acoziborole, Could Boost Efforts to Wipe Out Sleeping Sickness
- Chocolate Male Supplement Recalled Over Hidden Erectile Dysfunction Drug
- Clinician Engagement: The Operating Lever Behind Margin and Throughput
- Your Anesthesia Subsidy: Key Questions Every Hospital C-Suite Must Answer
- Amid unfolding Middle East war, pharma giants keep close eye on employee safety, supply chains
- CMS set to suspend enrollment in Elevance Health's Medicare Advantage plans
- Kennedy adds 2 new members to CDC’s vaccine panel ahead of delayed meeting
- Kennedy adds 2 new members to CDC’s vaccine panel ahead of delayed meeting
- Urban Traffic Noise Disrupts Sleep, Affects Heart Health After One Night
- Hormone Therapy Might Be Unnecessary For Some Prostate Cancer Patients
- Benzodiazepine Use Down In U.S., But OD Risk Remains, Study Says
- GLP-1 Drugs Might Ease Chronic Migraine, Study Says
- Blood Test Reveals Alcohol-Related Liver Disease
- Telemedicine Visits Cost Five Times Less Than In-Clinic Care
- Families Defend Disability Services Amid Medicaid Cuts
- Medicaid Is Paying for More Dental Care. GOP Cuts Threaten To Reverse the Trend.
- Bavarian Nordic CEO to follow board chair out the door after failed private equity takeover
- Ascendis gains more altitude with FDA approval for dwarfism drug Yuviwel
- CDMO Quotient extends Ipsen supply pact for rare disease drug Sohonos
- Quest Diagnostics launches Google-powered AI chatbot to help patients understand lab results
- Tennr takes aim at phone call bottlenecks as it builds out automation for patient referral process
- DoseSpot, Arrive Health merge to combine prescribing tools with pharmacy, medical benefit data
- Why Digital Tool are Needed to Cope with Increasing Pressures in MedTech Innovation
- Why Digital Tool are Needed to Cope with Increasing Pressures in MedTech Innovation
- Electronics Pollution Pose Added Threat to Endangered Dolphins, Porpoises
- Flea And Tick Pills May Pose Environmental Risks, Study Finds
- ICE, ALS, Addiction Medicine, and Robotic Ultrasounds: Journalists Sound Off on All That and More
- 11 behavioral health executive moves to know
- 3 behavioral healthcare M&A deals in 2026
- Anthem Blue Cross of California pushes E/M downcoding policy to April
- Iowa dentist surrenders license
- Temple University gets approval for $3.19M rural dental clinic
- A Canadian Hospital Scoops Up Nurses Who No Longer Feel Safe in Trump’s America
- Statement on the Adoption of Final Rules Under the Holding Foreign Insiders Accountable Act
- Statement on Final Rules for the Holding Foreign Insiders Accountable Act
- State Medicaid budgets to weather $664B reduction through 2034 due to OBBBA: RAND
- Clover Health CEO said company sees opportunity in complex MA environment
- How pharma marketers are capturing the power of podcasts to connect with consumers
- Cigna's Evernorth quietly acquires hospital pharmacy CarepathRx
- Walgreens debuts virtual weight management clinic with access to GLP-1 meds
- New Obamacare Rules Could Raise Deductibles to $31K For Families
- Study Suggests One Common Amino Acid May Affect How Long Men Live
- Merck to wind down Gardasil production at N.C. plant, lay off 150-plus
- Walmart Great Value Cottage Cheese Recalled Over Pasteurization Issue
- Chris Bosh Says He’s 'Lucky To Be Alive' After Sudden Health Scare
- Patrick Kennedy: Collab with MAHA is essential to address mental health crisis
- Lilly debuts Nvidia supercomputer with fanfare and focus on escaping traditional pharma lifecycle
- Alignment CEO John Kao offers measured response to proposed 2027 MA rates
- Sanofi, Genentech, Kedrion back star-studded bleeding disorder awareness campaign
- Op-ed: Our patients deserve better safety reporting. AI could be the answer
- After CHMP nod, Moderna CEO applauds EU's 'rigorous scientific review'
- UCB's fast-growing Bimzelx leaps across blockbuster sales threshold as HS momentum builds
- How the Brain Learns to Have Seizures During Sleep
- Blood Test Can Predict Short-Term Survival Among Seniors
- Why Turning 19 Spikes Medicaid Loss for Millions
- Crash Course Might Speed Brain Stimulation Treatment For Depression, Study Suggests
- Wildfire Smoke Linked To Increase In Violent Assaults
- More Parents Are Refusing A Life-Saving Shot For Their Newborns, Study Finds
- He Needs an Expensive Drug. A Copay Card Helped — Until It Didn’t.
- To Avoid Care Disruptions, Know When the Clock Runs Out on Your Prior Authorization
- As SCOTUS takes on 'skinny label' review, top US lawyer sides with generics maker
- Lake Nona Impact Forum: There can't be longevity without tech
- Fierce Pharma Asia—China deal growth; Daiichi's new CMO; Astellas-Vir bispecific tie-up
- Autoimmune CAR-T: Navigating the FDA’s new regulatory playbook
- FDA Approval for BIOTRONIK Solia CSP S Pacing Lead For LBBAP
- FDA Approval for BIOTRONIK Solia CSP S Pacing Lead For LBBAP
- Catalyst OrthoScience gets FDA 510(k) Clearance of Archer® Patient-Specific Instrumentation for Shoulder Arthroplasty
- Catalyst OrthoScience gets FDA 510(k) Clearance of Archer® Patient-Specific Instrumentation for Shoulder Arthroplasty
- Smith+Nephew signs distribution agreement with SI-BONE
- Smith+Nephew signs distribution agreement with SI-BONE
- Quantum Surgical Acquires NeuWave Medical, Inc.
- Quantum Surgical Acquires NeuWave Medical, Inc.
- How Pharma is Expanding its Global Footprint to Advance Clinical Research
- Partnering to Advance Drug Delivery Innovation
- What the Health? From KFF Health News: What About the State of Health?
- Teladoc Health reports slower growth, offers cautious 2026 outlook as it shifts telehealth model
- CFO Mark Kaye to take the helm at Carelon in leadership shake-up at Elevance Health
- Insurance groups say proposed flat Medicare Advantage rates fail to meet the moment
- Health Gorilla urges court to toss lawsuit filed by Epic, health systems
- Stryker launches Synchfix™ EVT, expanding options for flexible syndesmotic fixation
- Stryker launches Synchfix™ EVT, expanding options for flexible syndesmotic fixation
- Democrat-Led States Sue Trump Administration Over Cuts to Childhood Vaccine Schedule
- CDC Vaccine Advisory Panel To Revisit COVID Shot Safety Next Month
- Frozen Blueberry Recall Issued Across Four States for Listeria
- Boehringer's Hernexeos secures speedy first-line expansion in FDA's 2nd national priority nod
- 'Like talking to a brick wall': Senate hearing takes aim at FDA's rare disease review process
- After delay, CDC vaccine panel sets new dates to discuss long COVID and mRNA shot safety
- Decision Criteria for Technology Commercialization of Medical Devices in 2026
- Decision Criteria for Technology Commercialization of Medical Devices in 2026
- Cientos de enfermeros estadounidenses dejan atrás el Estados Unidos de Trump y eligen trabajar en Canadá
- Continuous Cardiac Monitoring: Redefining the “End” of a Clinical Study?
- Continuous Cardiac Monitoring: Redefining the “End” of a Clinical Study?
- Could Drone-Delivered Defibrillators Save Lives?
- Inflammation Linked To Brain Damage, Memory Problems Among Football Players
- Early Birds, Active Folks Less Likely To Develop ALS
- Disasters Can Affect Mental Health A Decade Later, Review Finds
- AI Chatbots Can Contribute To Worsening Mental Illness, Study Finds
- Newborns Exposed to More ‘Forever Chemicals’ Than Once Thought
- Study Highlights Unique Parenting Struggles of Younger Patients With Heart Disease
- Altman-backed startup Verifiable rolls out AI agent to automate credentialing
- ‘You Aren’t Trapped’: Hundreds of US Nurses Choose Canada Over Trump’s America
- ‘Kind of Morbid’: Health Premiums Threaten Their Nest Egg. A Terminal Diagnosis May Spare It.
Child deaths from marijuana ingestion increase after each state legalization. Packaging marijuana edibles like popular foot items sure doesn't help.
Commission demands firms immediately change unfair and deceptive packaging
July 5, 2023
As part of its ongoing monitoring of health-related advertising claims, the Federal Trade Commission today sent cease and desist letters – jointly with the U.S. Food and Drug Administration (FDA) – to six companies currently marketing edible products containing Delta-8 tetrahydrocannabinol (THC) in packaging that is almost identical to many snacks and candy children eat, including Doritos tortilla chips, Cheetos cheese-flavored snacks, and Nerds candy.
“Marketing edible THC products that can be easily mistaken by children for regular foods is reckless and illegal,” said Samuel Levine, Director of the FTC’s Bureau of Consumer Protection. “Companies must ensure that their products are marketed safely and responsibly, especially when it comes to protecting the well-being of children.”
“Children are more vulnerable than adults to the effects of THC, with many who have been sickened and even hospitalized after eating ‘edibles’ containing it. That’s why we’re issuing warnings to several companies selling copycat food products containing delta-8 THC, which can be easily mistaken for popular foods that are appealing to children and can make it easy for a young child to ingest in very high doses without realizing it,” said Janet Woodcock, M.D., Principal Deputy Commissioner, FDA.
The agencies sent letters to the following companies: 1) Delta Munchies LLC (Los Angeles, California); 2) Exclusive Hemp Farms (Gilroy, California) and Etienne-DuBois, LLC/Oshipt (Henrico, Virginia); 3) North Carolina Hemp Exchange, LLC, dba NC Hemp Shoppe (Raleigh, North Carolina; 4) Dr. Smoke, LLC, aka Dr. S, LLC (Kansas City, Missouri); 5) Nikte's Wholesale, LLC (Albuquerque, New Mexico); and 6) The Haunted Vapor Room (Franklin, New Jersey).
According to the letters, after reviewing online marketing for Delta-8 THC products sold by the six companies, the FTC has determined that their advertising may violate Section 5 of the FTC Act, which prohibits unfair or deceptive acts in or affecting commerce, including practices that present unwarranted health or safety risks. The letters stress that preventing practices that present such risks, particularly to children, is one of the Commission’s highest priorities, and that imitating non-THC-containing food products that children consume is misleading.
The companies’ Delta-8 THC products mimic a range of food that appeal to children. Dr. Smoke, LLC, for example, sells THC-infused “Doritos” that are marketed in packaging that is nearly the same as that of Doritos Nacho Cheese Flavored Tortilla Chips (see graphic), including using the same red background, the use of the Doritos name and triangle logo, and the depiction of two tortilla chips in the same position. In addition, Dr. Smoke’s THC-infused “Cheetos” are sold in packaging that is nearly identical to that of Cheetos Crunchy Flamin’ Hot Cheese Flavored Snacks, right down to the use of the Chester Cheetah mascot.
Another company, The Haunted Vapor Room, sells Delta-8 THC products called Rope 500mg Delta-8 Nerds Candy and Medicated Dope Rope Bites (see graphic) that closely resemble Nerds Rope candy, with both comprising multi-colored crunchy candies attached to a gummy rope, and packaging for the former using what appears to be the Nerds candy mascot.
A third company, Delta Munchies, LLC, markets Delta-8 THC gummies that look like conventional gummy candies that are often consumed by children (see graphic). The brightly colored packaging includes images of the products in fruity and sour flavors that the FTC contends enhance their appeal to children and increases the likelihood that they will mistakenly eat them, thinking they are traditional gummy candies.
In the letters, the FTC demands the companies stop marketing edible Delta-8 THC products that imitate conventional foods using advertising or packaging that is likely to appeal to young children. The FTC also strongly encourages the sellers to review all of their marketing and product packaging for similar edible THC products, and to take swift action and steps to protect consumers, especially young children, from these products.
Finally, the FTC has asked each company to contact agency staff within 15 days to detail the specific actions it has taken to address the Commission’s concerns. The primary staff attorney on this matter is Christine DeLorme in the FTC’s Bureau of Consumer Protection.
Colorful graphics for specific products are shown in article photos.
Published yesterday by the Annals of Internal Medicine, a response to one of the pre-legalization claims: that medical marijuana access would help chronic pain patients transition from standard pain medications.
The article is eligible for CME Point-of-Care and MOC credits.
Full research accessible from the summary page: https://doi.org/10.7326/M23-0053
Original Research | 4 July 2023By Emma E. McGinty, PhD, Kayla N. Tormohlen, PhD, Nicholas J. Seewald, PhD, Mark C. Bicket, MD, PhD, Alexander D. McCourt, JD, PhD, Lainie Rutkow, JD, PhD, Sarah A. White, MS, and Elizabeth A. Stuart, PhDEffects of U.S. State Medical Cannabis Laws on Treatment of Chronic Noncancer Pain
Abstract
Background:
State medical cannabis laws may lead patients with chronic noncancer pain to substitute cannabis in place of prescription opioid or clinical guideline–concordant nonopioid prescription pain medications or procedures.
Objective:
To assess effects of state medical cannabis laws on receipt of prescription opioids, nonopioid prescription pain medications, and procedures for chronic noncancer pain.
Design:
Using data from 12 states that implemented medical cannabis laws and 17 comparison states, augmented synthetic control analyses estimated laws’ effects on receipt of chronic noncancer pain treatment, relative to predicted treatment receipt in the absence of the law.
Setting:
United States, 2010 to 2022.
Participants:
583 820 commercially insured adults with chronic noncancer pain.
Measurements:
Proportion of patients receiving any opioid prescription, nonopioid prescription pain medication, or procedure for chronic noncancer pain; volume of each treatment type; and mean days’ supply and mean morphine milligram equivalents per day of prescribed opioids, per patient in a given month.
Results:
In a given month during the first 3 years of law implementation, medical cannabis laws led to an average difference of 0.05 percentage points (95% CI, −0.12 to 0.21 percentage points), 0.05 percentage points (CI, −0.13 to 0.23 percentage points), and −0.17 percentage points (CI, −0.42 to 0.08 percentage points) in the proportion of patients receiving any opioid prescription, any nonopioid prescription pain medication, or any chronic pain procedure, respectively, relative to what we predict would have happened in that month had the law not been implemented.
Limitations:
This study used a strong nonexperimental design but relies on untestable assumptions involving parallel counterfactual trends. Statistical power is limited by the finite number of states. Results may not generalize to noncommercially insured populations.
Conclusion:
This study did not identify important effects of medical cannabis laws on receipt of opioid or nonopioid pain treatment among patients with chronic noncancer pain.
Primary Funding Source:
National Institute on Drug Abuse.
Get MHF Insights
News and tips for your healthcare freedom.
We never spam you. One-step unsubscribe.
















